Healthcare
Wednesday, April 27, 2016
BRIEF-Celldex Therapeutics says initiates phase 1/2 study of Glembatumumab Vedotin in squamous cell lung cancer
* Says initiates phase 1/2 study of Glembatumumab Vedotin in
squamous cell lung cancer
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment